No connection

Search Results

ANL vs PRE

ANL
Adlai Nortye Ltd.
BEARISH
Price
$7.95
Market Cap
$293.4M
Sector
Healthcare
AI Confidence
85%
PRE
Prenetics Global Limited
NEUTRAL
Price
$17.83
Market Cap
$300.9M
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
ANL
--
PRE
--
Forward P/E
ANL
-31.18
PRE
-26.22
P/B Ratio
ANL
36.98
PRE
1.64
P/S Ratio
ANL
--
PRE
3.26
EV/EBITDA
ANL
-21.02
PRE
-6.5

Profitability

Gross Margin
ANL
0.0%
PRE
52.98%
Operating Margin
ANL
0.0%
PRE
-33.27%
Profit Margin
ANL
0.0%
PRE
-63.13%
ROE
ANL
-138.98%
PRE
-31.79%
ROA
ANL
-29.81%
PRE
-11.02%

Growth

Revenue Growth
ANL
--
PRE
248.6%
Earnings Growth
ANL
--
PRE
--

Financial Health

Debt/Equity
ANL
5.63
PRE
0.01
Current Ratio
ANL
1.02
PRE
3.01
Quick Ratio
ANL
0.69
PRE
2.76

Dividends

Dividend Yield
ANL
--
PRE
--
Payout Ratio
ANL
0.0%
PRE
0.0%

AI Verdict

ANL BEARISH

Adlai Nortye Ltd. (ANL) exhibits severe financial distress, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health—alongside a dangerously high Debt/Equity ratio of 5.63 and negative ROE of -138.98%. The company shows no profitability, with zero margins and negative earnings, while its Price/Book ratio of 36.98 suggests extreme overvaluation relative to book value. Despite a recent 1Y return of +247.2%, this surge appears speculative rather than fundamentals-driven, with no analyst consensus and no dividend or cash flow generation. The absence of key valuation metrics and the lack of sustainable growth signals make the current price unsustainable.

Strengths
Recent strong short-term price momentum (+247.2% 1Y, +345.4% 6M)
High analyst target price ($31.00) indicating potential upside expectation
Market cap ($0.29B) places it in a small-cap biotech niche with high volatility potential
Risks
Piotroski F-Score of 1/9 signals severe financial deterioration and poor operational efficiency
Negative ROE (-138.98%) and ROA (-29.81%) indicate deep losses and capital destruction
Debt/Equity ratio of 5.63 is extremely high, signaling significant leverage risk
PRE NEUTRAL

Prenetics Global Limited presents a high-risk, high-reward profile characterized by explosive revenue growth (248.6% YoY) contrasted with deep operational losses. The Piotroski F-Score of 4/9 indicates a stable but not strong financial position, while the absence of an Altman Z-Score is mitigated by an exceptionally low Debt/Equity ratio (0.01) and strong liquidity (Current Ratio 3.01). While analysts maintain a 'strong_buy' rating with a target of $31.25, the 0/100 technical trend and low insider sentiment (40/100) suggest significant near-term headwinds despite the long-term growth trajectory.

Strengths
Hyper-growth revenue trajectory (248.6% YoY, 567.66% Q/Q)
Pristine balance sheet with negligible debt (Debt/Equity 0.01)
Strong liquidity position with a Current Ratio of 3.01
Risks
Severe lack of profitability (Profit Margin -63.13%)
Bearish technical trend (0/100) indicating negative price momentum
Low insider sentiment (40/100) suggesting lack of internal confidence

Compare Another Pair

ANL vs PRE: Head-to-Head Comparison

This page compares Adlai Nortye Ltd. (ANL) and Prenetics Global Limited (PRE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile